Fate Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Fate Therapeutics

03/05/2023 23:38

* Fate Therapeutics Inc  FATE.OQ  reported a quarterly
adjusted
loss of 19 cents​​ per share for the quarter ended in March. The
mean expectation of twenty two analysts for the quarter was
for a loss of 62 cents per share.
    * Revenue rose 220.3% to $58.98 million from a year ago;
analysts
expected $35.50 million. 
    * Fate Therapeutics Inc's reported EPS for the quarter was a
loss
of 19 cents​.
    * The mean earnings estimate of analysts had risen by
about 9.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Fate Therapeutics Inc shares had risen by 3.9% this
quarter and
lost 41.3% so far this year.
    * The company reported a quarterly loss of $18.88 million.
    * Wall Street's median 12-month price target for Fate
Therapeutics
Inc is $7.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 14
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
3 at 10:38 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.62          -0.19          Beat
 Dec. 31 2022      -0.86          -0.58          Beat
 Sep. 30 2022      -0.89          -0.86          Beat
 Jun. 30 2022      -0.83          -0.79          Beat